NEWS
Our Announcements

2021

2020

2019

2018

OMass Unveils Rich Drug Discovery Pipeline Targeting Intractable or Inadequately Drugged Membrane and Complex-bound Proteins
OMass Unveils Rich Drug Discovery Pipeline Targeting Intractable or Inadequately Drugged Membrane and Complex-bound Proteins     Oxford, United Kingdom...

OMass Therapeutics appoints Dr Nathalie Franchimont as Non-Executive Director
Oxford, 28 July 2020 – OMass Therapeutics (“OMass”), a biopharmaceutical company harnessing native mass spectrometry and other high definition biophysical...

OMass Announces Publication in Nature Methods
Oxford, 15 May 2020 – OMass Therapeutics (“OMass”), a biotechnology company harnessing native mass spectrometry to drive drug discovery in...
OMass Announces Acquisition of Pharmacology Capabilities from Excellerate Biosciences
Oxford, 25 February 2020 - OMass acquires a pharmacology team led by industry expert, Professor Steven Charlton - OMass Therapeutics...
OMass Therapeutics Announces £27.5 Million Extended Series A Financing
Oxford, 17 February 2020 – Developing a pipeline of small molecule therapeutics for patients with immunological and genetic disorders OMass...
OMass Therapeutics’ Founder & Scientific Advisor, Professor Carol Robinson, receives a Royal Society Medal
Oxford, 23 July 2019 – OMass Therapeutics (“OMass”), a drug discovery company using structural mass spectrometry to discover novel medicines,...

OMass Therapeutics’ Founder & Scientific Advisor Honoured – Professor Carol Robinson wins 2019 Novozymes Prize and Stein & Moore Award –
Oxford, 16 July 2019 – OMass Therapeutics (“OMass”), a drug discovery company using structural mass spectrometry to discover novel medicines,...
OMass Therapeutics appoints Jonathan Montagu as Non-Executive Director
Oxford, 12 June 2019 – OMass Therapeutics (“OMass”), a drug discovery company using structural mass spectrometry to discover novel medicines,...
OMass Therapeutics appoints Rosamond Deegan as Chief Executive Officer
Oxford, 8 May 2019 – OMass Therapeutics (“OMass”), a drug discovery company using structural mass spectrometry to discover novel medicines,...
DyNAbind and OMass Therapeutics enter collaboration agreement
Dresden, Germany, 16.04.2019 – DyNAbind GmbH and OMass Therapeutics have entered a collaboration for the discovery of new fragment- and...
OMass Therapeutics Expands its Senior Leadership Team
Oxford, 27 November 2018 – OMass Therapeutics (“OMass”), a biotechnology company using structural mass spectrometry to discover novel medicines, today...

OMass Therapeutics is Expanding its Team
Oxford, 20 November 2018 – OMass Therapeutics (“OMass”), a biotechnology company using structural mass spectrometry to discover novel medicines is...
OMass Technologies Announces Publication Demonstrating the Impact of Lipid interactions on GPCR Signalling in Nature
Oxford, 11 July 2018 – OMass Technologies (“OMass”), a biotechnology company using structural mass spectrometry to drive drug discovery, today...
OMass Therapeutics Announces £14 Million Series A Financing to Build a Pipeline of Proprietary Medicines
Oxford, 20 November 2018 – Developing novel medicines using structural mass spectrometry – OMass Therapeutics (“OMass”), a biopharmaceutical company using...
OMass Technologies secures INNOVATE UK funding in collaboration with the University of Oxford
Oxford, 15 June 2017 – OMass Technologies (“OMass”), a biotechnology company using structural mass spectrometry to drive drug discovery, today...